PD-1抑制剂治疗的高危肺部毛玻璃样病变患者的活性和免疫动力学：来自单臂II期试验的见解
核心信息
- 论文英文标题: The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial
- 期刊: Signal Transduct Target Ther
- 发表年份: 2024
- DOI: 10.1038/s41392-024-01799-z
- PMID/PMCID: 38637495; PMC11026465
研究概览
The primary endpoint was objective response rate (ORR). This is a single-arm, phase II trial (NCT04026841) using Simon's optimal two-stage design, of which 4 doses of sintilimab (200 mg per 3 weeks) were administrated in 36 enrolled multiple primary lung cancer (MPLC) patients with persistent high-risk (Lung-RADS category 4 or had progressed within 6 months) GGOs.
核心发现
Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) protein significantly improve survival in patients with advanced non-small-cell lung cancer (NSCLC), but its impact on early-stage ground-glass opacity (GGO) lesions remains unclear.
This is a single-arm, phase II trial (NCT04026841) using Simon's optimal two-stage design, of which 4 doses of sintilimab (200 mg per 3 weeks) were administrated in 36 enrolled multiple primary lung cancer (MPLC) patients with persistent high-risk (Lung-RADS category 4 or had progressed within 6 months) GGOs.
The primary endpoint was objective response rate (ORR).
T/B/NK-cell subpopulations, TCR-seq, cytokines, exosomal RNA, and multiplexed immunohistochemistry (mIHC) were monitored and compared between responders and non-responders.
Echo Biotech 角色
血浆外泌体分离鉴定及长链RNA测序分析
关联平台: Exoomics®, Research Reagents & Tools
关联服务与能力: Biofluid EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV lncRNA/mRNA Sequencing, Research Reagent / Product Supply
关联产品或试剂: Exosupur® EV Isolation/Purification Kit
参考文献
原始论文: The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial Signal transduction and targeted therapy. 2024. DOI: 10.1038/s41392-024-01799-z. PMID/PMCID: 38637495; PMC11026465.